NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) — Strategic Asset Allocation Index
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has a Strategic Asset Allocation Index of 7.3% as of September 2025. Strategic assets (PP&E of $- plus long-term investments of $53.09 Million) total $53.09 Million, measured against net assets of $728.07 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See NAMS equity financing ratio to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
NewAmsterdam Pharma Company N.V. Ordinary Shares Strategic Asset Allocation Index (2020–2021)
This chart shows how NewAmsterdam Pharma Company N.V. Ordinary Shares's Strategic Asset Allocation Index has evolved across 2 annual periods from 2020 to 2021. As of September 2025, the index stands at 7.3%, representing strategic assets of $53.09 Million against net assets of $728.07 Million USD. For live market cap and overall valuation, see market value of NewAmsterdam Pharma Company N.V. Ordinar.
Annual Strategic Asset Allocation Index for NewAmsterdam Pharma Company N.V. Ordinary Shares (2020–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for NewAmsterdam Pharma Company N.V. Ordinary Shares from 2020 to 2021, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See what is NewAmsterdam Pharma Company N.V. Ordinar's book value for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 0.3% | $190.00K | $190.00K | $- | $56.63 Million | ▲ +0.3 pp |
| 2020 | 0.0% | $12.00K | $12.00K | $- | $127.46 Million | — |